STAT+: Roivant lung disease drug hits mid-stage study goals — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Mosliciguat achieved a 56% placebo-adjusted reduction in pulmonary vascular resistance — a measure of blood pressure and flow in the artery connecting the heart to the lungs — in Roivant's 16-week Phase 2 study
- The drug also produced a 35-meter placebo-adjusted improvement in six-minute walk distance, a key secondary endpoint for exercise capacity
- NT-proBNP, a blood-based marker of heart failure, fell 53% on a placebo-adjusted basis, meeting another secondary endpoint with statistical significance
- A positive Phase 2 readout could establish a new treatment approach for pulmonary hypertension, a serious lung disease where current options remain limited
- Roivant would gain a second potential blockbuster medicine, strengthening the biotech's financial position if Phase 3 trials confirm the effect
Why it matters: Pulmonary hypertension is a serious, underserved lung disease, and the 56% reduction in pulmonary vascular resistance — far exceeding the effect typical of existing therapies — positions mosliciguat as a potentially differentiated mechanism if Phase 3 confirms it, while giving Roivant a second revenue-driving asset to supplement its pipeline.
Ask SkimNews
